{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T13:47:31Z","timestamp":1792417651387,"version":"4.4.0"},"reference-count":17,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2024,3,20]],"date-time":"2024-03-20T00:00:00Z","timestamp":1710892800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Purpose<\/jats:title>\n<jats:p>To examine the association of several antihypertensive medication classes with incidence of Parkinson\u2019s disease (PD), taking into account possible underlying conditions.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods<\/jats:title>\n<jats:p>In a case-control study based on a large primary care database and including 21,981 PD cases and 21,981 non-PD controls matched for age, sex, and possible treatment indications associations with different antihypertensive medication groups, including diuretics, betablockers, calcium channel blockers, angiotensin-converting enzyme inhibitors and angiotensin-II receptor-blockers and PD were examined.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>Antihypertensive medications overall were associated with a lower risk of subsequent diagnosis of PD (OR: 0.94, 95% CI 0.90\u20130.97), with the negative association most significant for medications acting on the renin\u2013angiotensin\u2013aldosterone system. A positive association with diagnosis of PD was only seen for betablockers and restricted to those with relatively young age and not in those with longer treatment duration.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusion<\/jats:title>\n<jats:p>When taking into account underlying diagnoses, antihypertensive medications overall were associated with a reduced incidence of PD.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0299985","type":"journal-article","created":{"date-parts":[[2024,3,20]],"date-time":"2024-03-20T17:29:12Z","timestamp":1710955752000},"page":"e0299985","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":2,"title":["Association of antihypertensives and Parkinson\u2019s disease in a primary care population matched for underlying diagnosis"],"prefix":"10.1371","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9872-6680","authenticated-orcid":true,"given":"Anette","family":"Schrag","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karel","family":"Kostev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2024,3,20]]},"reference":[{"key":"pone.0299985.ref001","doi-asserted-by":"crossref","first-page":"837890","DOI":"10.3389\/fphar.2022.837890","article-title":"Protective Effect of Renin-Angiotensin System Inhibitors on Parkinson\u2019s Disease: A Nationwide Cohort Study","volume":"13","author":"Y. Jo","year":"2022","journal-title":"Front Pharmacol"},{"issue":"10","key":"pone.0299985.ref002","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1080\/13543784.2017.1371133","article-title":"Renin-angiotensin system as a potential target for new therapeutic approaches in Parkinson\u2019s disease","volume":"26","author":"S. Perez-Lloret","year":"2017","journal-title":"Expert Opin Investig Drugs"},{"issue":"2","key":"pone.0299985.ref003","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/pds.5176","article-title":"Using artificial intelligence to identify anti-hypertensives as possible disease modifying agents in Parkinson\u2019s disease","volume":"30","author":"N.P. Visanji","year":"2021","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"7","key":"pone.0299985.ref004","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1093\/aje\/kwr362","article-title":"Use of calcium channel blockers and Parkinson\u2019s disease","volume":"175","author":"B. Pasternak","year":"2012","journal-title":"Am J Epidemiol"},{"issue":"1","key":"pone.0299985.ref005","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1186\/s13287-021-02585-2","article-title":"In vitro genome editing rescues parkinsonism phenotypes in induced pluripotent stem cells-derived dopaminergic neurons carrying LRRK2 p.G2019S mutation","volume":"12","author":"K.H. Chang","year":"2021","journal-title":"Stem Cell Res Ther"},{"key":"pone.0299985.ref006","doi-asserted-by":"crossref","first-page":"120009","DOI":"10.1016\/j.jns.2021.120009","article-title":"The association between developing Parkinson\u2019s disease and beta-Adrenoceptor acting agents use: A systematic review and meta-analysis","volume":"430","author":"W. Saengphatrachai","year":"2021","journal-title":"J Neurol Sci"},{"issue":"3","key":"pone.0299985.ref007","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S1474-4422(19)30400-4","article-title":"beta-adrenoreceptors and the risk of Parkinson\u2019s disease","volume":"19","author":"F. Hopfner","year":"2020","journal-title":"Lancet Neurol"},{"issue":"2","key":"pone.0299985.ref008","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1001\/jamaneurol.2022.3902","article-title":"Widening the Spectrum of Risk Factors, Comorbidities, and Prodromal Features of Parkinson Disease","volume":"80","author":"A. Schrag","year":"2023","journal-title":"JAMA Neurol"},{"key":"pone.0299985.ref009","doi-asserted-by":"crossref","first-page":"162","DOI":"10.3389\/fneur.2018.00162","article-title":"Hypertension and Diagnosis of Parkinson\u2019s Disease: A Meta-Analysis of Cohort Studies","volume":"9","author":"L. Hou","year":"2018","journal-title":"Front Neurol"},{"issue":"16 Pt 2","key":"pone.0299985.ref010","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1212\/01.wnl.0000303818.38960.44","article-title":"Use of antihypertensives and the risk of Parkinson disease","volume":"70","author":"C. Becker","year":"2008","journal-title":"Neurology"},{"issue":"10","key":"pone.0299985.ref011","doi-asserted-by":"crossref","first-page":"459","DOI":"10.5414\/CP203320","article-title":"Basic characteristics and representativeness of the German Disease Analyzer database","volume":"56","author":"W. Rathmann","year":"2018","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"2","key":"pone.0299985.ref012","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s15010-022-01895-8","article-title":"Association between antihypertensive medication and the risk of urinary tract infection (UTI) of outpatients: a retrospective cohort study","volume":"51","author":"N. Gremke","year":"2023","journal-title":"Infection"},{"issue":"1","key":"pone.0299985.ref013","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1159\/000520574","article-title":"Identification of Prodromal Presentations of Parkinson\u2019s Disease among Primary Care Outpatients in Germany","volume":"56","author":"J. Bohlken","year":"2022","journal-title":"Neuroepidemiology"},{"issue":"10","key":"pone.0299985.ref014","doi-asserted-by":"crossref","first-page":"483","DOI":"10.5414\/CP203559","article-title":"The association between antihypertensive therapy and the incidence of Parkinson\u2019s disease in patients followed in general practices in Germany","volume":"57","author":"A. Warda","year":"2019","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"8","key":"pone.0299985.ref015","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.amjmed.2022.04.029","article-title":"Association of Angiotensin Receptor Blockers with Incident Parkinson Disease in Patients with Hypertension: A Retrospective Cohort Study","volume":"135","author":"H.C. Lin","year":"2022","journal-title":"Am J Med"},{"issue":"10","key":"pone.0299985.ref016","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1038\/s41593-018-0234-x","article-title":"The role of brain vasculature in neurodegenerative disorders","volume":"21","author":"M.D. Sweeney","year":"2018","journal-title":"Nat Neurosci"},{"key":"pone.0299985.ref017","doi-asserted-by":"crossref","first-page":"117412","DOI":"10.1016\/j.jns.2021.117412","article-title":"Calcium Channel blockers are associated with reduced risk of Parkinson\u2019s disease in patients with hypertension: A population-based retrospective cohort study","volume":"424","author":"Y.F. Tseng","year":"2021","journal-title":"J Neurol Sci"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0299985","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,20]],"date-time":"2024-03-20T17:29:31Z","timestamp":1710955771000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0299985"}},"subtitle":[],"editor":[{"given":"Hean Teik","family":"Ong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,3,20]]},"references-count":17,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,3,20]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0299985","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,20]]}}}